Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.
about
Systemic therapies for pancreatic cancer--the role of pharmacogeneticsKRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFRGenetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinoma.Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma.Basic principles and technologies for deciphering the genetic map of cancer.pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinomaTargeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of actionEGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.Epidermal growth factor receptor in pancreatic cancer.Erlotinib in the treatment of advanced pancreatic cancerEGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.Lack of evidence for prognostic value of epidermal growth factor receptor intron-1 CA repeats for oral carcinomas.EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.Sensitization of Radiation or Gemcitabine-Based Chemoradiation Therapeutic Effect by Nimotuzumab in Pancreatic Cancer Cells.
P2860
Q27021716-5285B2F0-9E9B-4CD6-AE86-A845A8B1059AQ27852101-1FC67221-6085-46CE-BEA6-596874E48C69Q33688445-2D829AC4-740C-4806-9D92-525FD4147080Q33779432-461B585D-F705-467D-B2FD-19DE25ADDEB1Q34017423-C7DD0080-D761-4B33-BC0F-4A3AE9BD8F41Q34074628-AC31AEDF-C79F-48B0-9696-AC39EEC94EFBQ34123654-8645D789-E360-47D5-AC23-B3F77DD6FA2FQ34582105-205C2F4D-CEDE-44AC-A71C-A96CE1835D28Q35208054-2587A19C-CA59-4E5E-B74C-048E67C3A90CQ36012730-6FAD8A49-C86C-446C-AAE9-8D0E11756E9DQ36475391-61473CC4-52CD-41F4-A193-506D6A989BA3Q36594155-D7DED5B9-9AFE-41A4-9E69-9EB15FD79E49Q37132640-2FE2574E-C318-48DC-960B-54B298AC0E02Q37307567-FCD040F2-6A61-4A87-9297-7EFF24ED7FA9Q38034817-E34BE00C-E252-456F-8218-0F9889E8BDFCQ40354546-665EF184-03B0-448F-A03C-0D41B922EA6CQ42520266-AA271966-A627-485D-9B66-3590FE7F4966Q46105210-27ECD5DB-179E-4F8A-B926-6B34ADAD4588Q52942376-25FE9A3B-8CFF-41B4-81EC-D6A432A98B5B
P2860
Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pancreatic cancer epidermal gr ...... d in vitro erlotinib response.
@en
type
label
Pancreatic cancer epidermal gr ...... d in vitro erlotinib response.
@en
prefLabel
Pancreatic cancer epidermal gr ...... d in vitro erlotinib response.
@en
P2093
P1476
Pancreatic cancer epidermal gr ...... d in vitro erlotinib response.
@en
P2093
Andrey Frolov
Ching-Wei D Tzeng
Donald J Buchsbaum
J Harrison Howard
J Pablo Arnoletti
Martin J Heslin
Natalya Frolova
Nirag C Jhala
Selwyn M Vickers
P2888
P304
P356
10.1245/S10434-007-9409-5
P577
2007-04-24T00:00:00Z
P6179
1012003209